Peptide Comparison
Semaglutide vs Tirzepatide
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both FDA-approved for type 2 diabetes. Mounjaro adds GIP agonism on top of GLP-1, producing larger reductions in HbA1c and body weight in head-to-head trials.
Semaglutide
Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrate significant reductions in body weight and cardiovascular risk markers. It works by enhancing insulin secretion, suppressing glucagon, and reducing appetite.
Semaglutide Clinical ReferenceTirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). It has shown superior weight loss outcomes compared to semaglutide in head-to-head trials. The dual-agonist mechanism provides enhanced metabolic benefits.
Tirzepatide Clinical ReferenceKey Differences
This comparison is informational and reflects content from TruthTides clinical reference documentation. It does not constitute medical advice. Only three peptides on TruthTides — semaglutide, tirzepatide, and tesamorelin — carry FDA approvals; many others are compounded or off-label. Consult a qualified physician before starting any peptide therapy.
Ask TruthSource AI
Which is right for me — Semaglutide or Tirzepatide?
Get a guardrailed, evidence-anchored answer based on your goals.
Open Reference ToolFind a Doctor
Find a physician who prescribes Semaglutide or Tirzepatide
Filter our directory by peptide, location, and telehealth availability.
Open Physician Finder